Disco Pharmaceuticals Secures €36M Seed Funding

Why It Matters

The sizable seed investment underscores growing investor confidence in ADC technology and strengthens Europe’s position in oncology drug development, while the leadership change aims to accelerate clinical progress.

Key Takeaways

• €36M seed round led by Ackermans, van Haaren, NRW.Bank.
• Focus on ADCs for SCLC and MSS‑CRC indications.
• Investors include AbbVie Ventures, Sofinnova, M Ventures, Panakes.
• New CEO Mark Manfredi replaces founder Roman Thomas.
• Funds target IND‑enabling studies and pipeline expansion.

Pulse Analysis

The antibody‑drug conjugate market is entering a rapid expansion phase, driven by the promise of delivering cytotoxic payloads directly to cancer cells while sparing healthy tissue. Disco Pharmaceuticals’ €36 million seed raise places it among the most well‑funded early‑stage ADC developers in Europe, signaling that venture capital and strategic investors see a clear path to value creation in this niche. By securing backing from both regional financiers like NRW.Bank and global biotech players such as AbbVie Ventures, Disco gains the financial runway and credibility needed to compete with larger multinational programs.

Disco’s scientific strategy centers on highly selective, surfaceome‑targeted bispecific ADCs and T‑cell engagers, a differentiated approach that could broaden the therapeutic window for notoriously hard‑to‑treat tumors. The company’s lead candidates target small‑cell lung cancer and microsatellite‑stable colorectal cancer—two indications with high unmet medical need and limited effective treatments. Advancing these assets toward IND‑enabling studies will allow Disco to generate pivotal preclinical data, attract further downstream funding, and potentially secure partnership deals that accelerate market entry.

The appointment of Mark Manfredi, a seasoned biotech executive, reflects a deliberate move to pair scientific ambition with seasoned operational leadership. Manfredi’s experience in scaling early‑stage companies is expected to streamline regulatory pathways and strengthen investor relations. Combined with a robust investor consortium, this leadership shift positions Disco as a compelling player in Germany’s burgeoning biotech ecosystem, where access to capital and talent is increasingly aligning with ambitious oncology pipelines.

Deal Summary

Disco Pharmaceuticals, a Cologne‑based biotech developing antibody‑drug conjugates, announced the close of a €36 million seed round. The financing was co‑led by Ackermans and van Haaren and NRW.Bank, with participation from Sofinnova Partners, AbbVie Ventures, M Ventures and Panakes Partners, and will fund IND‑enabling studies for its cancer pipeline.